Emirodatamab Biosimilar – Anti-FLT3;CD3E mAb – Research Grade from ProteoGenix; catalogue PX-TA1833; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Emirodatamab Biosimilar is a novel monoclonal antibody (mAb) that targets FLT3 and CD3E, two important proteins involved in the development and progression of certain types of cancer. This research grade antibody has shown promising results in preclinical studies and is currently being evaluated in clinical trials as a potential therapeutic option for cancer patients.
Emirodatamab Biosimilar is a recombinant humanized IgG1 monoclonal antibody. It is composed of two identical heavy chains and two identical light chains, each containing a variable and a constant region. The variable regions of the heavy and light chains are responsible for binding to FLT3 and CD3E, respectively. The constant regions of the antibody are responsible for effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).
Emirodatamab Biosimilar binds to both FLT3 and CD3E with high affinity and specificity. FLT3 is a receptor tyrosine kinase that is overexpressed in many types of cancer, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). By binding to FLT3, Emirodatamab Biosimilar inhibits its activity and prevents the proliferation and survival of cancer cells. CD3E is a protein found on the surface of T cells, which are important immune cells that play a role in fighting cancer. By binding to CD3E, Emirodatamab Biosimilar activates T cells and enhances their ability to recognize and kill cancer cells.
Emirodatamab Biosimilar has shown promising results in preclinical studies as a potential treatment for various types of cancer. In AML and ALL, Emirodatamab Biosimilar has been shown to inhibit the growth and survival of cancer cells and induce T cell-mediated killing of cancer cells. It has also been evaluated in other types of cancer, such as non-Hodgkin’s lymphoma and solid tumors, with promising results.
In addition to its potential as a therapeutic agent, Emirodatamab Biosimilar can also be used in research settings to study the role of FLT3 and CD3E in cancer development and progression. Its high specificity and affinity make it a valuable tool for studying these proteins and their interactions with other molecules.
Emirodatamab Biosimilar is a novel monoclonal antibody that targets FLT3 and CD3E, two important proteins involved in cancer development and progression. Its unique structure and activity make it a promising therapeutic option for various types of cancer. In addition, it can also be used as a research tool to study the role of FLT3 and CD3E in cancer. Further clinical trials will determine the full potential of Emirodatamab Biosimilar as a therapeutic agent for cancer patients.
ProteoGenix catalogue number PX-TA1833. For research use only.
Target: Emirodatamab Biosimilar – Anti-FLT3;CD3E mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Emirodatamab Biosimilar – Anti-FLT3;CD3E mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
